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Divalent ion metabolism in patients with acute renal failure:
Studies on the mechanism of hypocalcemia. Studies were carried
out in ten patients with acute renal failure to characterize certain
features of deranged divalent ion metabolism. During the
oliguric period, the patients displayed hypocalcemia, hyper-
phosphatemia, hypermagnesemia and elevated levels of immuno-
reactive parathyroid hormone. Hypocalcemia and elevated
levels of immunoreactive parathyroid hormone persisted into
the diuretic phase while serum phosphorus and magnesium
often fell to or below normal. No correlation was found between
concentrations of serum calcium and phosphorus, while there
was an inverse correlation between those of immunoreactive
parathyroid hormone and serum calcium. The concentrations of
ionized calcium were low, and the percent of total calcium bound
to protein was normal. The infusion of parathyroid extract
during the oliguric and diuretic phases failed to elicit a normal
rise in serum calcium concentration. When renal function had
returned to normal, serum calcium and phosphorus values and
the response to the infusion of parathyroid extract were normal.
Resistance to the calcemic action of infused parathyroid extract
was also found in thyroparathyroidectomized dogs after three
days of acute uremia. These studies demonstrate that hypo-
calcemia and secondary hyperparathyroidism occur early in the
course of acute renal failure, and the results indicate that
resistance to the skeletal action of parathyroid hormone plays an
important role in the genesis of these abnormalities.
Métabolisme des ions divalents chez les malades atteints d'insuf-
fisance rénale aigu: Etude du mécanisme de l'hypocalcémie. Dix
malades atteints d'insuffisance rénale aiguë ont été étudiés afin
de caractériser certains aspects de l'altération du métabolisme
des ions divalents. Au cours de Ia période oligurique il existe une
hypocalcemie, une hyperphosphatémie, une hypermagnésémie
et des concentrations élevées d'hormone parathyroIdienne
immunoréactive. L'hypocalcémie et l'augmentation de Ia con-
centration d'hormone parathyroldienne immunoréactive persis-
tent au cours de Ia phase diuretique alors que le phosphate et Ic
magnesium plasmatiques sont souvent inférieurs aux valeurs
normales. Aucune correlation n'a été trouvée entre les concen-
trations plasmatiques de calcium et de magnesium alors qu'une
correlation inverse existait entre Ia concentration d'hormone
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parathyroIdienne immunoréactive et Ia concentration plasmati-
que du calcium. La concentration du calcium ionisé est basse et
Ia fraction du calcium total liée aux protéines est normale. La
perfusion d'extrait parathyroIdien au cours des phases oliguri-
que et diurétique n'induit pas l'augmentation normalement
attendue de Ia concentration du calcium plasmatique. Après le
retour a Ia normale de Ia fonction rénale, Ia réponse a l'extrait
parathyroidien devient normale. La résistance a l'action hyper-
calcémiante de l'extrait parathyroidien perfuse a été observée
aussi après troisjours d'urémie aiguë chez des chiens thyropara-
thyroIdectomises. Ces travaux montrent que l'hypocalcemie et
l'hyperparathyroidisme secondaire surviennent précocément au
cours du déroulement de l'insuffisance rénale aiguë et les résul-
tats indiquent que Ia résistance a l'action osseuse de l'hormone
parathyroIdienne joue un role important dans Ia génése de ces
anomalies.
Secondary hyperparathyroidism and elevated blood
levels of immunoreactive parathyroid hormone are
almost always found in patients with chronic renal
failure [1, 2]. It is generally accepted that the stimulus
for this phenomenon is the hypocalcemia which occurs
as renal insufficiency ensues. Bricker et al [3] suggested
that the hypocalcemia in patients with chronic renal
failure is secondary to the phosphate retention that
occurs following the reduction in functional renal
mass; data from experimental animals provided sup-
port for this postulate [4]. Massry et al [5] showed
that resistance to the skeletal action of parathyroid
hormone develops early in the course of chronic renal
failure in man, and they suggested that this abnor-
mality may play a major role in the pathogenesis of
hypocalcemia.
A fall in the concentration of total serum calcium is
noted in patients with acute renal failure [6, 7]. The
mechanisms responsible for the hypocalcemia of acute
renal failure are not defined. Phosphate retention and
hyperphosphatemia, resistance to the skeletal action of
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parathyroid hormone and a fall in plasma protein
concentration or alterations in protein binding of
calcium may each or all be contributory. Data re-
garding parathyroid gland activity and divalent ion
metabolism during the oliguric and diuretic phase of
acute renal failure and after recovery from the disease
are limited [7—9]. Transient hypercalcemia has been
reported in a few patients during the diuretic phase of
acute renal failure [7—10].
The present study was undertaken to evaluate
systematically certain aspects of divalent ion metab-
olism in patients with acute renal failure and to
elucidate the mechanisms underlying the hypo-
calcemia in these patients.
Methods
Studies in humans. Ten patients were studied during
the oliguric and diuretic phases of acute renal failure,
and five of the patients were reevaluated after the
return of renal function to normal. The patient popu-
lation consisted of eight women and two men, and
their ages ranged from 30 to 75 years. The clinical
features of the patients are presented in Table 1.
Informed consent was obtained either from the
patient or their families, or from both. The studies
were initiated immediately upon admission of the
patients to the Mt. Sinai Division of the Cedars-Sinai
Medical Center.
Blood samples were withdrawn daily or every other
day for the measurement of the concentrations of
creatinine, calcium, magnesium, phosphorus and
immunoreactive parathyroid hormone. The concen-
trations of diffusible calcium and magnesium and
those of ionized calcium in blood were determined
two to three times each week; the concentration of
albumin in blood was measured at least once during
both the oliguric and diuretic phases of the disease.
The calcemic response to the i.v. infusion of para-
thyroid extract (Eli Lilly Co., Indianapolis, Indiana),
given in 500 ml of 5% dextrose in water at a dose
of 1 U/kg/hr for the ten hours from 8 AM to 6 PM,
was evaluated in 11 normal subjects and in ten
patients with acute renal failure with most of the
patients evaluated during both the oliguric and diure-
tic phases of the disease and in five of these patients
after recovery of renal function. The same batch of
parathyroid extract was used in all studies, and its
potency was assessed by measuring both the calcemic
and phosphaturic responses in dogs. Since the
maximum elevation in serum calcium concentration
was noted in the normal subjects either at the end of
the parathyroid extract infusion (6 PM) or two hours
later (8 PM), the calcemic response to parathyroid
extract infusion in the patients was calculated from
the difference between the concentration of serum
calcium before the infusion and the highest of the
values observed at 6 or 8 PM. The blood levels of
immunoreactive parathyroid hormone were measured
before and upon completion of the infusion of para-
thyroid extract. Creatinine, phosphorus, calcium and
magnesium were measured by methods previously
reported [5]. Levels of immunoreactive parathyroid
hormone were determined by radioimmunoassay [II],
utilizing antisera to bovine parathyroid hormone and
standards of partially purified human parathyroid
hormone (HPTH); the upper limit of the normal
value by this assay is 4 l of HPTH/ml. The diffusible
fractions of calcium and magnesium were determined
in ultrafiltrates of serum prepared by anaerobic ultra-
Table 1. Clinical features of patients with acute renal failure
Patient
No.
Age,
years
Sex Cause of acute Initial study,
renal failure davs after onset
Duration of
oliguria,
Therapy
days
1 74 M Sepsis hypotension 7 21 Hemodialysis x 6
2 59 F Dehydration 5 3—4
3 36 F Diarrhea dehydration 15 6—7
4 43 F Transfusion reaction 2 15 Hemodialysis x 4
5 56 F Diarrhea & vomiting 2
(colostomy), dehydration
9
6 75 F Sepsis after 4
cholecystectomy
39 Hemodialysis x 8
7 30 M Postoperative 3
laminectomy
13 Peritoneal dialysis x I
Hemodialysis x 2
8 72 F Pancreatitis 27 32 (died) Hemodialysis, numerous occasions
9 45 F Diarrhea, vomiting 5
dehydration cholecystography
12 Peritoneal dialysis x 2
10 34 F Postoperative 3
hysterectomy
10
Hospitalized elsewhere; exact duration of oliguria uncertain.
12 1 oliguric phase
•
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Serum phosphorus, mg/IOO nil
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filtration at room temperature [12]. The concentration
of ionized calcium was measured by a micromodifica-
tion of the method of Ettori and Scoggan [13]. Water
content of serum was determined by refractometry
(Goldberg refractometer, American Optical Co.,
Buffalo, N.Y.). Serum albumin concentration was
determined by electrophoresis.
Studies in dogs. An elevation in endogenous levels of
parathyroid hormone during acute renal failure could
affect the calcemic response to the infusion of para-
thyroid extract. To exclude this possibility, studies
were carried out in thyroparathyroidectomized dogs.
Thyroparathyroidectomy was performed in five dogs,
with success of the procedure ascertained by the
development of hypocalcemia. The calcemic response
to the i.v. infusion of parathyroid extract, 2 U/kg/hr
for eight hours, was evaluated in the same animals
three days after thyroparathyroidectomy and again
after three days of acute uremia produced by bilateral
ligation of the ureters. The change in the concentration
of serum calcium was calculated as the difference be-
tween the control values and that observed on com-
pletion of the infusion of parathyroid extract.
Results
The serum concentrations of creatinine, total
calcium and magnesium, phosphorus, albumin and
immunoreactive parathyroid hormone in the ten
patients with acute renal failure are shown in Table 2.
The concentrations of diffusible calcium and magne-
sium and of ionized calcium are also presented in
Table 2.
During the oliguric phase (urine volume less than
500 ml), hypocalcemia was invariably noted and
occurred as early as two days after the onset of the
renal failure. The lowest values of serum calcium
observed in the various patients ranged from 5.3 to
7.5 mg/100 ml, and the mean values of multiple
measurements ranged between 6.3 0.56 (sEM) and
8.3 0.21 mg/l00 ml. The fractions of total serum
calcium identified as diffusible and ionized were not
different from those observed in normal subjects [14];
the absolute value in these moieties were also lower
than normal. Hypocalcemia usually persisted during
the diuretic phase, although the mean values of serum
calcium were higher in four of the seven patients
evaluated during both phases of the disease. Transient
hypercalcemia developed in one patient during the
diuretic phase. The concentration of serum calcium
returned to normal in the five patients evaluated after
the recovery of renal function.
Hyperphosphatemia occurred in all patients during
the oliguric phase. The maximum elevation in serum
phosphorus concentration was mild (serum phos-
phorus, 5.2 to 5.5 mg/100 ml) in three patients and
moderate to severe in the others. During the diuretic
period the levels of serum phosphorus were normal or
low in four patients; in the other five patients the
concentrations were initially high but fell gradually to
normal or low levels. The concentrations of serum
phosphorus were normal after recovery of renal failure.
1-lypermagnesemia was present in all but one patient
during the oliguric phase. The highest values noted in
the various patients ranged between 2.2 and 4.6 mg/
100 ml. During the diuretic phase the serum magne-
sium concentration fell to normal or slightly low
levels. The magnesium concentration in serum was
normal after recovery of renal function.
The relationship between the concentrations of
serum calcium and phosphorus for all measurements
made during the oliguric and diuretic phases are
shown in Figs. 1 and 2, respectively. There was no
correlation between these two indexes, and hypo-
calcemia was observed with low, normal or elevated
serum phosphorus concentration.
The levels of immunoreactive parathyroid hormone
were persistently elevated in all but one patient during
the oliguric phase. During the diuretic period the
concentrations of immunoreactive parathyroid hor-
mone in blood were still high in each case except the
patient who had normal values during the oliguric
phase. Fig. 3 depicts the relationship between the
concentration of immunoreactive parathyroid hor-
mone and total calcium in blood for all measurements
made during both the oliguric and diuretic periods of
the illness. There was a significant inverse correlation
between the blood levels of immunoreactive para-
Fig. 1. Relationship between the concentrations of serum calcium
and phosphorus in patients studied during the oliguric phase of
acute renal failure. Each point represents a separate measurement.
Shaded areas represent the normal ranges.
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Table 2. Values of serum creatinine, phosphorus, calcium, magenesium and
Patient
No.
Oligunc phase
S' S SMg SAIb
g/IUO ml
iPTH
jl of !-i'PTI-IJml
mg/lOU ml
1 Mean±sEM 15.8±0.59 6.6±0.43 7.9±0.13 3.0±0.12 3.0 14,2±2.00
Range 13.0—18.0 4.9—9.0 7.4—8.6 2.1—3.8 5—19
2 Mean±sEM
Range
3 Mean SEM
Range
4 Mean±sEM 10.9±0.81 6.7±0.62 8.2±0.19 2.7±0.18 3.6 9,6±1.39
Range 7.6—14.3 3.9—9.8 7.4—9.1 1.7—3.9 5—15
5 Mean±sEM 7.0±0.89 7.5±0.55 6.3±0.56 1.8±0.14 2.8 17.5±3.4
Range 3.6—9.2 6.0—8.7 5.3—8.3 1.6—2.2 11—26
6 Mean±sEM 7.8±0.20 4.1±0.24 7.9±0.22 2.7±0.07 3.6 3.5±0.45
Range 6.1—8.6 2.9—5.2 6.7—9.5 2.2—3.5 1—6
7 Mean±sEM 15.5±2.44 8.3±0.02 8.1±0,21 3.7±0.28 3,2 9.8±1.46
Range 6.0—23.7 6.4—11.0 6.9—8.5 3.1—4.6 6—13
8 Mean±sEM 11.4±3.2 4.9±0.32 7.8±0.39 4.0±0.15 3.8 7.3±0.38
Range 5.5—16.3 4.5—5.5 7.0—8.3 3.7—4.3
9 Mean±sEM 16.3±1.45 5.4±0.04 7.5±0.47 3.5±0.19 3.1 12.5±1.59
Range 10.7—19.1 5.3—5.5 6.8—8.4 3.2—4.2 8—18
10 Mean±sEM 15.7±2.14 4.5±0.36 8.3±0.2! 3.3±0.08 2,4 11.6±1.21
Range 8.0—22.6 3.0—6.4 7.5—9.0 2.9—3.5 6—15
S, serum creatinine; S, serum phosphorus; S, serum calcium; S0, serum magnesium; SAIb, serum albumin; iPTH, immunoreactive
parathyroid hormone and HPTH, human parathyroid hormone. Each data point represents the mean of five to eight determinations.
Table 3. The levels of the diffusible fractions of calcium and magnesium and of ionized calcium in the blood of patients with acute
renal failure0
Patient
No.
Calcium Magnesium
Total Diffusible %
Diffusibility
Ionized
mg/IOU ml
%
Ionized
Total Diffusible %
Diffusibility
mg/IOU mlmg/lOU ml
1 Oliguric phase 7.8±0.07 5.0±0.11 63.4± 1.34 4.2±0.19 49.5±2.39 2.9±0.17 2.2±0.14 77.9±0.94
Diuretic phase 7.8±0.32 4.8±0.15 62.2± 1.53 4.4±0.18 53.6± 1.30 1.7±0.20 1.3±0.16 77.9±1.35
2 Diureticphase 7.7±0.16 4.9±0.10 62.9±0.76 4.0±0.13 51.1±0.85 1.4±0.10 1.0±0.10 73.9±1.53
3 Diureticphase 9.0±0.24 6.0±0.33 66.3±0.85 5.2±0.09 57.5±0.63 1.7±0.18 1.3±0.05 74.3±1.44
4 Oliguricphase 7.8±0.05 4.8±0.05 61.8±1.18 3.8±0.04 48.5±0.50 2.8±0.31 2.1±0.25 73.7±1.05
Diuretic phase 9.2±0.10 5.8±0.11 62.5±0.64 4.7±0.09 49.8±0.75 2.0±0.14 1.5±0.16 74.0±1.36
5 Oliguric phase 6.3±0.40 4.0±0.31 63.5± 1.04 3.1±0.21 49.3±0.42 1.8±0.12 1.3±0.09 75.0±0.70
Diuretic phase 8.0±0.15 5.1±0.10 63.4± 1.14 4.2±0.10 52.6±0.50 1.2±0.09 0.9±0.09 75.6±0,67
6 Oliguric phase 8.3±0.29 5.2±0.12 65.8±0.90 4.1±0.10 52.3± 1.05 3.2±0.58 2.4±0.16 75.5± 1.93
Diureticphase 8.7±0.30 5.6±0.10 64.5±1.69 4.8±0.25 55.2±1.51 2.4±0.10 1.9±0.06 77.0±070
7 Oliguricphase 8.3±0.09 5.3±0.10 63.3±1.88 4.1±0.28 48.5±0.28 3.4±0.22 2.5±0.14 73.0±0.57
Diuretic phase 9.7±0.22 5.9±0.15 60.7±0.80 4 9±0.11 49.9±0.85 2.3±0.28 1.7±0.21 75.0± 1.00
8 Oliguric phase 7.8±0.39 5.0±0.28 64.0±0.57 4.0±0.15 51.0±0.57 4.0±0.17 3.0±0.14 76.0±0.57
9 Oliguric phase 7.7±0.47 5.0±0.25 65.3± 1.45 4.0±0.28 51.7±0.66 3.3±0.05 2.5±0.08 76.0±3.05
Diuretic phase 8.5±0.35 5.4±0.20 63.7±0.33 4.6±0.18 54.7±0.33 2.2±0.38 1.7±0.30 78.0± 1.15
10 Oliguric phase 8.9±0.15 5.7±0.15 63.5± 1.04 3.3±0.12 2.6±0.10 77.0±0.57
Diuretic phase 9.4±0.12 5.9± 0.09 62.5 2.1 1.9 76.3
Each value represents the mean of three to seven measurements ISEM.
12 1 o Diuretic phase
0 2 6 8 10 12
Serum phosphorus, m'/1OO ml
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immunoreactive parathyroid hormone in patients with acute renal failures
Diuretic phase Recovery
Scr SF SMg SAIb
g/100 ml
iPTH
iil of HP TB/mi
Scr S SMg iPTH
l of HP TI-I/mi
mg/100 ml mg/IOO ml
7.6±1.34 3.1±0.16 7.9±0.20 1.6±0.17 3.8 15.6±1.04
1.7—13.2 2.6—4.2 6.4—8.9 1.1—2.2 7—25
2.0±0.29 3.5±0.11 8.0±0.11 1.4±0.04 3.4 9.3±0.99
1.2—4.5 2.7—4.1 7.4—S.4 1.1—1.5 4—15
7.9±1.77 4.5±1.27 9.3±0.26 2.1—10.12 3.8 11±2.91 0.8 3.1 9.7 2.2 1
2.6—17.4 2.9—10.8 8.6—10.2 1.7—2.6
7.0±1.06 5.6±0.90 9.4±0.06 2.2±0.17 3.4 8.1±1.52 1.2 3.1 9.3 1.7 8
2.3—10.5 3.0—9.2 9.2—9.6 1.6—3.0
5.4±0.28 3.6±0.15 8.0±0.29 1.3±0.06 3.0 10.0±2.53
6.5—4.0 3.0—4.2 5.7—8.6 1.0—1.7 2—21
4.9±0.65 1.9±0.24 8.9±0.20 2.3±0.09 2.9 2.7±1.28
3.4—7.3 1.4—2.7 8—9.3 2.0—2.5 1—9
6.7± 1.51 6.0±0.74 9.6±0.26 2.4±0.16 3.8 7.7± 1.03 1.3 2.7 9.7 1.8 1
1.6—24.8 3.3—11.6 8.6—11.9 1.7—4.0 2—15
11.5±2.38 4.7±0.70 8.3±0.18 2.2±0.14 3.4 13.3±0.73 0.9 3.4 9.7 2.2 2
3.4—20.5 2.5—7.3 7.4—8.7 1.8—3.0 10—16
7.6± 1.52 3.9±0.42 8.7±0.20 2.0±0.08 2.6 12.1 0.9 4.5 10.1 1.8 2
1.6—1 7.2 2.4—6.8 7.7—9.8 1.7—2.6 6—20
thyroid hormone and calcium (Y =34.7—2.9X, where
Y is the level of immunoreactive parathyroid hormone
and X the concentration of serum calcium).
The results of the infusions of parathyroid extract
are given in Table 4. The infusion of parathyroid
extract did not cause a significant increase in serum
calcium concentration in any patient studied during
the oliguric and diuretic phases. In contrast, serum
calcium increased by 1.2 to 1.8 (1.4±0.14, mean±
SCM) mg/l00 ml during the infusion of parathyroid
extract which was administered after recovery of renal
function. This calcemic response was not different
from the increase of 1.3 0.14 mg/ 100 ml in 11 normal
subjects studied in our laboratory [5]. The failure of
uremic patients to respond to parathyroid extract
occurred when the concentrations of serum phosphorus
and magnesium were normal or elevated and in the
face of a substantial increase in the blood levels of
immunoreactive parathyroid hormone induced by the
parathyroid extract infusion.
3.
1-
a)
20:
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Fig. 2. Relationship between concentrations of serum calcium and
phosphorus during the diuretic phase of acute renal failure (see
legend for Fig. 1).
Fig. 3. The relation between the level of immunoreactive para-
thyroid hormone (PTH) and that of serum calcium in patients with
acute renal failure. Each point represents a separate measurement.
U
E
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o Diuretic phaseY = 34.7—2.9X
4
Serum calcium, mg/100 ml
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Table 4. Effect of infusion of parathyroid extract on serum calcium in patients with acute renal failurea
Patient
No.
Phase of
ARF
Days
after
onset
Serum values
iPTH
Cr Mg
Calcium
P Before After Before After
PTE PTE PTE PTE
infusion infusion infusion infusion
mg/lOG nil ul ofHPTH/,nl
I Oliguric
Diuretic
13
41
14.0
3.0
3.1
2.2
7.2 8.0
3.5 8.4
8.0
8.6
0.0
+0.2
5 50
14 70
2 Diuretic
Diuretic
12
18
2.1
1.4
1.3
1.4
3.6 7.4
3.4 8.1
7.5
8.3
+0.1
+0.2
9 120
8 >200
3 Diuretic
Recovery
21
125
6.3
0.8
1.7
2.2
4.1 9.2
3.1 9.7
9.6
10.9
+0.4
+1,2
17 >200
1 120
4 Oliguric
Diuretic
Recovery
6
22
41
11.7
4.3
1.2
2.4
1.8
1.7
5.0 7.6
3.1 9.5
3.1 9.3
7.8
9.6
11.1
+0.2
+0.1
+1.8
8 175
14 >200
8 200
6 Oliguric
Diuretic
18
45
8.2
3.5
3.8
3.4
5.2 8.3
1.4 8.9
8.1
8.9
—0.2
0.0
4 100
9 >200
7 Oliguric
Diuretic
Recovery
8
29
37
17.3
3.2
1.3
3.1
2.2
1.8
6.6 8.3
2.6 9.8
2.9 9.7
8.4
9.6
10.9
+0.1
—0.2
+1.2
13 90
5 80
1 40
8 Oliguric 27 15.5 4.3 4.6 8.3 8.2 —0.1 7 60
9 Oliguric
Diuretic
Recovery
11
21
125
19.1
3.4
0.9
3.3
1.8
2.2
5.3 8.4
2.5 8.7
3.4 9,7
8.0
9.1
10.9
—0.4
+0.4
+1.2
16 120
10 >200
2 120
10 Oliguric
Diuretic
Recovery
8
24
49
19.0
2.2
0.9
3.5
1.7
1.8
5.0 9.0
2.9 9.8
4.5 10,1
9.2
9.8
11.8
+0.2
0.0
+1.7
16 120
8 90
2 100
Mean Oliguric 15.0 3.4 5.6 8.57 8.44 —0.03 9,4
Diuretic
Recovery
3.3
1.0
2.0
1.9
3.0 8.86
3.4 9.68
9.00
11.10
+0.14
+1.42
10.6
1.32
2.8
Mg, magnesium; F, phosphorus; PTE, parathyroid exti'act; iPTH, immunoreactive para-ARF, acute renal failure; Cr, creatinine;
thyroid hormone.
Studies in dogs. The effects of the infusion of para-
thyroid extract in thyroparathyroidectomized dogs
before and after the induction of acute uremia are
shown in Table 5. Hypocalcemia was of a similar
magnitude in the animals before and after bilateral
ureteral ligation. The rise in serum calcium concentra-
tion following the infusion of parathyroid extract
during the uremic state was 0.3±0.14 mg/100 ml, a
mean value significantly lower than the increment of
1.9±0.36 mg/lOOml observed in the same dog prior
to the induction of uremia (P<0.001).
Discussion
The present study describes a systematic evaluation
of certain aspects of deranged metabolism of divalent
ions in patients with acute renal failure. The patients
displayed hypocalcemia, hyperphosphatemia, hyper-
magnesemia and elevated levels of immunoreactive
parathyroid hormone. The hypocalcemia was of
moderate to marked degree, occurred early in the
course of the oliguric phase of the disease and persis-
ted into the diuretic period.
Theoretically, several factors may contribute to the
hypocalcemia of acute renal failure. Among these are
hyperphosphatemia [4], hypomagnesemia and mag-
nesium depletion [15], hypoalbuminemia or alterations
in calcium binding by serum proteins [16, 17], failure
of parathyroid gland function and skeletal resistance
to the action of parathyroid hormone.
Although an elevation in serum phosphorus con-
centration can cause a fall in serum calcium, it is
unlikely that the hyperphosphatemia observed in
these patients was the primary cause of the hypo-
calcemia. The latter occurred when serum phosphorus
concentration was low, normal or elevated; and there
was no correlation between the concentrations of
serum calcium and phosphorus for the entire patient
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Table 5. Effect of the infusion of parathyroid extract on serum calcium in thyroparathyroidectomized dogs before and after the
induction of acute uremiaa
Dog No. Se,. Serum calcium Serum phosphorus
Before PTE After PTE Before PTh After PTE
mg/lOU ml
I Normal
Uremic
0.6
10.2
7.9
7.2
10.5 +2.6
7.3 +0.1
4.1
7.4
1.8
7.4
2 Normal
Uremic
1.0
10.1
5.9
6.7
8.4 +2.6
7.5 +0.7
7.5
6.5
4.5
6.1
3 Normal
Uremic
0.7
9.4
7.7
5.9
8.4 +0.7
6.2 +0.3
4.7
10.8
2.0
9.9
4 Normal
Uremic
0.7
10.6
6.4
6.5
8.7 +2.3
7.0 +0.5
5.9
10.8
3.1
10.8
5 Normal
Uremic
0.7
10.5
5.7
6.1
7.2 +1.5
6.1 0
4.3
16.0
1.6
15.2
Mean Normal 0.7±0.06 6.7±0.45 8.6±0.53 1.9±0.36 5.3±0.62 2.6±0.54
Uremic 10.2±0.21 6.5±0.51 6.8±0.28 0.3±0.12 10.3±1.66 99±1.57
' Sr, serum creatinine; PTE, parathyroid extract.
population. The observations that hypocalcemia was
noted in association with elevated serum magnesium
values during the oliguric phase and with normal or
slightly low magnesium values during the diuretic
period indicate that magnesium depletion did not play
an important role in the genesis of hypocalcemia.
The hypoalbuminemia observed in some of the patients
was not severe enough to totally account for the degree
of hypocalcemia; a decrease of 1.0 g/l00 ml in serum
albumin has been estimated to be associated with a fall
in the concentration of total serum calcium of 0.8 to
1.0 mg/100 ml [16, 17]. Furthermore, the possibility
that alterations in the binding of calcium by serum
proteins could have caused the hypocalcemia seems
remote since the percent diffusibility of serum calcium
was not changed.
The elevated levels of immunoreactive parathyroid
hormone during the oliguric phase of renal failure
present a clear demonstration that hyperactivity of the
parathyroid glands occurs early in the course of acute
renal failure in man, a finding that is in agreement with
observations of Kovithavongs, Becker and Ing in
patients with acute renal failure [7] and with the results
of Jastak, Morrison and Raisz in rats [18]. The present
data clearly exclude the existence of failure of the
function of the parathyroid glands, and the inverse
relationship between the concentrations of serum
calcium and immunoreactive parathyroid hormone
indicates that the parathyroid glands in acutely uremic
patients are responsive to hypocalcemia.
The existence of such elevated levels of immuno
reactive parathyroid hormone in association with low
concentrations of blood calcium suggests skeletal
resistance to the calcemic actions of parathyroid hor-
mone, if the immunoreactive hormone is biologically
active. Support for the presence of such skeletal
resistance to parathyroid hormone action is provided
by the results following the infusion of parathyroid
extract. Serum calcium failed to increase in the patients
with acute renal failure as it did in normal subjects
despite the substantial elevation in the levels of im-
munoreactive parathyroid hormone following this
infusion. A rise in the concentration of serum calcium
after the administration of parathyroid extract is
primarily caused by the mobilization of bone calcium
into the extracellular fluid. Several factors may modify
this effect, including hyperphosphatemia, hypo-
magnesemia, a marked preexisting elevation of the
levels of endogenous parathyroid hormone and the
presence of excess osteoid.
It is unlikely that the impaired response to para-
thyroid extract is due to hyperphosphatemia, since
parathyroid extract failed to elevate serum calcium
concentration during both the oliguric and diuretic
phases, when serum phosphorus was elevated, normal
or low. Magnesium depletion can lead to an impaired
calcemic response to parathyroid hormone [15]; the
blood concentrations of magnesium were normal or
elevated at the time of the infusion of parathyroid
extract (Table 3). These values bore no relationship to
the response to parathyroid extract infusion.
Three observations militate against the possibility
that preexisting elevations of the levels of parathyroid
hormone may reduce the response to the infusion of
parathyroid extract. First, Evanson found that patients
with parathyroid adenoma have a normal response to
the infusion of parathyroid extract [19}; Massry et a!
reported that the reduced calcemic response to the
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infusion of parathyroid extract in patients with
chronic renal failure was not improved after they had
undergone subtotal parathyroidectomy with a marked
reduction in the preinfusion blood levels of immuno-
reactive parathyroid hormone [5]. Finally, the results
of the present studies in thyroparathyroidectomized
dogs demonstrate that acute uremia leads to a
diminished calcemic response to the infusion of para-
thyroid extract in the absence of endogenous para-
thyroid hormone.
It seems unlikely that there could have been accumu-
lation of excess osteoid in an amount adequate to
alter the response to parathyroid extract during the
short period of acute renal failure. In one study of
bone biopsy specimens in a few patients with acute
renal failure, there was evidence of a mild increase in
bone resorption without evidence of increased
osteoid [20].
The acute phosphaturic response and subsequent
hypophosphatemia which follow the administration of
parathyroid extract may be necessary for a normal
calcemic effect of the hormone. The absence of this
renal action during the oliguric phase of acute renal
failure and in the animals with ureteral ligation may
have accounted, in part, for the diminished calcemic
response to parathyroid extract. However, patients
with early to moderate renal failure demonstrated a
reduced calcemic response to parathyroid extract
despite a marked phosphaturic action [5]. Also, in the
present study, there was a lack of calcemic action to
parathyroid extract during the diuretic phase despite
moderate to marked hypophosphatemia.
The present data are consistent with the presence of
skeletal resistance to the calcemic action of para-
thyroid hormone in acute renal failure; such a resis-
tance could play a paramount role in the genesis of
hypocalcemia and the development of secondary
hyperparathyroidism in these patients. The data also
indicate that there is reversal of the hypocalcemia and
secondary hyperparathyroidism and improvement of
the skeletal response to parathyroid extract to normal
following the restoration of normal renal function.
The mechanism for such skeletal resistance has not
been elucidated by the results of the present study, but
several possibilities may be considered: First, the
retention of some toxic factors due to acute renal
failure might directly alter the metabolism of bone
and its response to parathyroid hormone. It is also
possible that toxic factors of uremia might alter para-
thyroid hormone, making it inactive at the bone level,
or greatly increased amounts of inactive fragments of
parathyroid hormone in uremia might displace the
biologically active form of the hormone from receptor
sites. Finally, it is possible that acute renal failure is
associated with reduced availability of the active meta-
bolite of vitamin D, 1,25-dihydroxycholecalciferol;
such an event may render the skeleton less responsive
to the calcemic action of parathyroid hormone.
1,25-Dihydroxycholecalciferol is produced in the mito-
chondria of the tubular cells of the renal cortex [21],
and acute tubular necrosis could theoretically lead to
reduced synthesis of this hormone. The precise rate of
plasma turnover of this steroid is not yet defined, but
it is believed to be quite rapid [22]. Therefore, it is
possible that patients with acute renal failure due to
tubular necrosis could develop a deficiency of 1,25-
dihydroxycholecalciferol within a very short time after
the onset of the disease.
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